Doctors and society convince us that developing various health issues and negative sy
Recently, a new generation of incretin-based therapies has emerged, including dual agonists that target the GLP-1/GIP receptors (e.g., tirzepatide) or the GLP-1/glucagon receptors (e.g., cotadutide and survodutide), as well as triple agonists that act on the GLP-1, GIP, and glucagon receptors (e.g., retatrutide) (Targher et al., 2023[76], 2025[77])
This contrasts with providers that openly use known pharmacies like Empower , Belmar , or Olympia
doi: 10.1186/s12967-024-05533-9 57 MurrayNAl KhalafSBastiaanssenTFSKaulmannDLonerganECryanJFet al
Oxidative stress as a common key event in developmental neurotoxicity
Theres no guarantee that these small doses wont cause big problems